Author:
Zhou Xiang,Xiao Xianghui,Kortuem Klaus Martin,Einsele Hermann
Reference113 articles.
1. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management;Rajkumar;Am J Hematol,2022
2. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma;Attal;N Engl J Med,2017
3. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial;Goldschmidt;Leukemia,2018
4. The epidemiology, management and impact of surgical wounds healing by secondary intention: a research programme including the SWHSI feasibility RCT;Chetter,2020
5. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial;Durie;Lancet,2017